Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 624

1.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
2.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

PMID:
17651658
[PubMed - indexed for MEDLINE]
Free Article
3.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Clark W, Jobanputra P, Barton P, Burls A.

Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.

PMID:
15130461
[PubMed - indexed for MEDLINE]
Free Article
4.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

PMID:
21439251
[PubMed - indexed for MEDLINE]
Free Article
5.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

PMID:
16948890
[PubMed - indexed for MEDLINE]
Free Article
6.

Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.

Doan QV, Chiou CF, Dubois RW.

J Manag Care Pharm. 2006 Sep;12(7):555-69. Review.

PMID:
16981801
[PubMed - indexed for MEDLINE]
Free Article
7.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

PMID:
21291629
[PubMed - indexed for MEDLINE]
Free Article
8.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

PMID:
21333232
[PubMed - indexed for MEDLINE]
Free Article
9.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
[PubMed - indexed for MEDLINE]
10.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
[PubMed - indexed for MEDLINE]
11.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

PMID:
16545208
[PubMed - indexed for MEDLINE]
Free Article
12.

Rituximab for the treatment of rheumatoid arthritis.

Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R.

Health Technol Assess. 2009 Sep;13 Suppl 2:23-9. doi: 10.3310/hta13suppl2/04. Review.

PMID:
19804686
[PubMed - indexed for MEDLINE]
Free Article
13.

Etanercept for the treatment of rheumatoid arthritis.

Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2013 May 31;5:CD004525. doi: 10.1002/14651858.CD004525.pub2. Review.

PMID:
23728649
[PubMed - indexed for MEDLINE]
14.

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Foster RH.

Pharmacoeconomics. 2004;22(2):107-32. Review.

PMID:
14731052
[PubMed - indexed for MEDLINE]
15.

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.

Health Technol Assess. 2004 Mar;8(11):iii, 1-91. Review.

PMID:
14982655
[PubMed - indexed for MEDLINE]
Free Article
16.

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.

PMID:
18405470
[PubMed - indexed for MEDLINE]
Free Article
17.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

PMID:
16904047
[PubMed - indexed for MEDLINE]
Free Article
18.

Golimumab for the treatment of psoriatic arthritis.

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review.

PMID:
21609657
[PubMed - indexed for MEDLINE]
Free Article
19.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
[PubMed - indexed for MEDLINE]
20.

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52. Review.

PMID:
18419803
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk